CSPC Pharmaceutical Group Limited (01093.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

16.8x

EV/EBITDA

4.9x

Market Cap

HKD 111.57B

MomentumView details →

1D Return

+0.78%

YTD Return

+14.89%

RSI (14)

64.4

ValuationView details →

P/E (Fwd)

16.8x

EV/EBITDA

4.9x

Market Cap

HKD 111.57B

RSI (14)

64.4

MomentumView details →

1D Return

+0.78%

YTD Return

+14.89%

ProfitabilityView details →

Gross Margin

69.53%

Net Margin

19.62%

EBITDA Margin

28.75%

ROE (TTM)

29.65%

ROA (TTM)

19.91%

Asset Turnover

1.11x

GrowthView details →

Revenue YoY

−10.28%

EPS YoY

−3.81%

FCF YoY

+23.24%

Revenue CAGR 3Y

−7.09%

EPS CAGR 3Y

−14.06%

EBITDA YoY

−7.21%

EarningsView details →

EPS (Actual)

HKD 0.62

EPS Surprise

277.22%

Beats (12Q)

1/12

Next Q EPS Est

HKD 0.29

Avg Surprise (4Q)

277.22%

Rev Surprise

39.01%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

2.14x

Quick Ratio

1.93x

Div Yield

2.99%

Div Rate

HKD 0.29

Div Growth 1Y

−37.50%

Financials snapshotView financials →

Revenue (TTM)

56.84B

Net Income (TTM)

11.15B

Op. CF (TTM)

9.29B

Next earningsMar 24, 2027 →

Latest newsMore news →

Shenzhen Sineuro Medical Technology Co., Ltd., a subsidiary of Sinomed, received a Class III medical device registration certificate from China's National Medical Products Administration for its delivery-type balloon dilation catheter, valid until August 30, 2031.3d ago

CSPC Pharmaceutical Group announced that its drug SYS6010 was again included in the National Medical Products Administration's Breakthrough Therapy Designation list for the treatment of recurrent or metastatic head and neck squamous cell carcinoma after failure of prior immunotherapy and platinum-based chemotherapy.3d ago

Similar companies

SanofiSNY GSK plcGSK Bristol-Myers Squibb CompanyBMY Pfizer Inc.PFE 片仔癀600436.SH PharmGen Science, Inc.004720.KS Find similar companies →

Latest newsMore news →

Shenzhen Sineuro Medical Technology Co., Ltd., a subsidiary of Sinomed, received a Class III medical device registration certificate from China's National Medical Products Administration for its delivery-type balloon dilation catheter, valid until August 30, 2031.3d ago CSPC Pharmaceutical Group announced that its drug SYS6010 was again included in the National Medical Products Administration's Breakthrough Therapy Designation list for the treatment of recurrent or metastatic head and neck squamous cell carcinoma after failure of prior immunotherapy and platinum-based chemotherapy.3d ago CSPC Pharmaceutical Group announced the initiation of the Phase II clinical trial for its weight-loss drug SYH2069 at the first research center in China.7d ago